Business · Companies · 38 mins ago

Celltrion leads biosimilar markets in major Asian countries

Celltrion leads biosimilar markets in major Asian countries

Celltrion says its biosimilars lead in major Asian markets for treatments of autoimmune diseases and cancer.

Biosimilars are medicines made to be highly similar to existing biological drugs.

The company says the position is based on market data from IQVIA and Celltrion.

Its Remsima product range treats autoimmune diseases and contains infliximab.

The available information gives no complete market-share figures for the countries mentioned.

Celltrion is expanding local direct sales and launching follow-up products, building on its current position.

These launches may broaden the company's range of biosimilar treatments in the region.

1 source

Related